Reed J A, McNutt N S, Bogdany J K, Albino A P
Department of Pathology, New York Hospital-Cornell University Medical Center, NY 10021, USA.
J Cutan Pathol. 1996 Dec;23(6):495-505. doi: 10.1111/j.1600-0560.1996.tb01441.x.
The molecular events responsible for tumor progression in human cutaneous malignant melanoma remain unclear; however, critical to the process is the dysregulated proliferation of tumor cells and the development of new vascular channels which allow further growth and dissemination. Connective tissue mast cells (MC) have been implicated in tumor progression because they concentrate around tumors (including melanomas) prior to the formation of new blood vessels, and because they contain many chemical mediators, including basic fibroblast growth factor (bFGF), known to have mitogenic and angiogenic effects. Several MC chemotactic and mitogenic factors have been described including interleukin-3 (IL-3). In order to determine whether there is a differential expression of this MC chemotactic/mitogenic factor with tumor progression in vivo, we evaluated by immunohistochemistry 85 melanocytic lesions including primary invasive malignant melanoma (PIMM), melanoma in situ (MMIS), and ordinary intradermal benign melanocytic nevi (BMN) for expression of IL-3. Nucleic acid in situ hybridization also was used to evaluate the melanocytic lesions for IL-3-specific mRNA transcripts. Intracellular IL-3 protein was detected in 29/33 (88%) PIMM and 15/25 (60%) MMIS, but was not detected in any (0/27; 0%) BMN (p < 0.0001). IL-3-specific mRNA transcripts were present in 3/4 PIMM and 2/10 MMIS in which IL-3 protein was not identified, but were not detected in any BMN. IL-3 mRNA or protein was not detected in normal melanocytes present in the perilesional epidermis of any of the specimens studied. Immunohistochemistry also was used to confirm the presence of IL-3 alpha-specific receptors on human cutaneous MC. As demonstrated by others, a significantly increased number of MC was present in the perilesional stroma of PIMM and MMIS vis a vis BMN (p < 0.0001). The results suggest that melanoma cells may attract MC in vivo by producing MC chemotactic/mitogenic factors such as IL-3. The recruitment of MC and the subsequent release of their potent mitogenic and angiogenic factors such as bFGF may thus represent a tumor-host interaction which favors tumor progression. Reed JA, McNutt NS, Bogdany JK, Albino AP. Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression.
人类皮肤恶性黑色素瘤中导致肿瘤进展的分子事件仍不清楚;然而,该过程的关键在于肿瘤细胞的增殖失调以及新血管通道的形成,这些新血管通道有助于肿瘤进一步生长和扩散。结缔组织肥大细胞(MC)与肿瘤进展有关,因为它们在新血管形成之前聚集在肿瘤(包括黑色素瘤)周围,并且它们含有许多化学介质,包括已知具有促有丝分裂和血管生成作用的碱性成纤维细胞生长因子(bFGF)。已经描述了几种MC趋化因子和促有丝分裂因子,包括白细胞介素-3(IL-3)。为了确定这种MC趋化/促有丝分裂因子在体内是否随肿瘤进展而有差异表达,我们通过免疫组织化学评估了85个黑素细胞病变,包括原发性浸润性恶性黑色素瘤(PIMM)、原位黑色素瘤(MMIS)和普通皮内良性黑素细胞痣(BMN)中IL-3的表达。核酸原位杂交也用于评估黑素细胞病变中IL-3特异性mRNA转录本。在29/33(88%)的PIMM和15/25(60%)的MMIS中检测到细胞内IL-3蛋白,但在任何BMN中均未检测到(0/27;0%)(p<0.0001)。在3/4的PIMM和2/10的MMIS中存在IL-3特异性mRNA转录本,其中未鉴定出IL-3蛋白,但在任何BMN中均未检测到。在所研究的任何标本的病变周围表皮中的正常黑素细胞中均未检测到IL-3 mRNA或蛋白。免疫组织化学也用于确认人皮肤MC上存在IL-3α特异性受体。正如其他人所证明的,与BMN相比,PIMM和MMIS病变周围基质中的MC数量显著增加(p<0.0001)。结果表明,黑色素瘤细胞可能通过产生IL-3等MC趋化/促有丝分裂因子在体内吸引MC。因此,MC的募集以及随后释放其强大的促有丝分裂和血管生成因子(如bFGF)可能代表了一种有利于肿瘤进展的肿瘤-宿主相互作用。里德JA、麦克纳特NS、博格达尼JK、阿尔比诺AP。黑素细胞病变中肥大细胞生长因子白细胞介素-3的表达与病变周围基质中肥大细胞数量增加相关:对黑色素瘤进展的影响。